Dance Biopharm Inc., of Brisbane, Calif., completed a $9.5 million financing consisting of convertible notes and warrants to a syndicate of individual and institutional investors. Proceeds will be used to fund clinical studies and to manufacture drug and devices for studies of Dance 501, the company's inhaled insulin candidate to treat diabetes, as well as for other corporate purposes.